Living guidelines for the pharmacological management of RA with DMARD (Canadian Rheumatology Association)

Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs

This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and patients, and incorporate a health equity framework developed for the Canadian RA population. Recommendations are added and updated in a living fashion over time. This online version of the guideline will have the latest recommendations, evidence summaries and evidence to decision frameworks, and can be accessed directly through MAGICapp or through the CRA website (www.rheum.ca).


Read full Guideline